Obesity Market

• In 2023, the United States accounted for the largest obesity market size (more than USD 2,000 Million) of obesity, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• Obesity is recognized as a chronic disease, which is a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity, or body fatness which can manifest metabolically and not just with respect to the size of the body.
• The US FDA has approved XENICAL (orlistat), QSYMIA (phentermine-topiramate), CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), and IMCIVREE (setmelanotide)—for long-term use in overweight and obesity treatment.
• Recently, in November 2023, the US FDA approved Eli Lilly and Company's ZEPBOUND (tirzepatide) injection, for the treatment of obesity that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptors.
• Among the all therapies, WEGOVY (Simaglutide) and ZEPBOUND (tirzepatide) are estimated to generate the highest revenue in the US.
• In December 2023, Pfizer announced topline data from the Phase IIb clinical trial (NCT04707313) investigating its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without Type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.
• In recent years, there has been a growing focus on the development of novel therapies for the treatment of obesity, including drug combinations such as SAXENDA (liraglutide), XENICAL (orlistat), WEGOVY (simaglutide), QYSMIA (phentermine-topiramate), and others.
• The obesity market dynamics in obese and overweight population is anticipated to change as companies across the globe are thoroughly working towards the development of new drug therapies for the management of this issue. Key obesity companies, such as Novo Nordisk, Eli Lilly, Boehringer Ingelhium, and others are involved in developing novel therapies for, overweight and obesity which will eventually help in the weight management.
• According to DelveInsight's estimates, the total number of prevalent cases of obesity among adults in the United States was approximately 60% of the cases in the 7MM in 2023.
• Obesity prevalence for the United States has shown an increasing trend in adult population. As per DelveInsight’s estimates, the total prevalent cases of obesity in the United States was highest for adults (>19 years) and for children (5–19 years), in 2023. These cases are anticipated to increase in both adults and children at moderate CAGR.

Request for unlocking the CAGR of the "Obesity Drug Market"

DelveInsight's “Obesity Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of obesity, historical and forecasted epidemiology as well as the obesity market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Obesity market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM obesity market size from 2020 to 2034. The report also covers current obesity treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Key Factors Driving the Obesity Market

Rising Global Prevalence of Obesity

Increasing sedentary lifestyles, poor dietary habits, and urbanization are fueling the obesity epidemic worldwide. With obesity linked to severe health conditions like type 2 diabetes, cardiovascular disease, and certain cancers, the need for effective interventions is expanding rapidly. As per DelveInsight analysis, the total prevalent cases of obesity are expected to rise from 191 million in 2024 to 221 million by 2034 across the leading markets (the US, EU4, the UK, and Japan).

Dominance of Novo and Eli Lilly in the Anti-Obesity Market

Currently, a significant chunk of the anti-obesity market is distributed among Novo Nordisk and Eli Lilly. Novo Nordisk’s WEGOVY (semaglutide) and Eli Lilly’s ZEPATETIDE (tirzepatide) are reshaping the anti-obesity drug market, with both vying for the top spot.

GLP-1 Agonists Redefining Obesity Care

Treatments based on GLP-1 agonists are transforming obesity management, evolving far beyond their original use in type 2 diabetes. These therapies not only regulate appetite and enhance metabolic control but also offer a safer, non-surgical alternative for patients struggling with obesity, potentially reshaping long-term treatment strategies.

Robust Obesity Clinical Trial Activity

The obesity clinical trial landscape includes several drugs in mid- and late-stage development that are expected to be approved in the near future. The expected launch of emerging therapies, such as Surrodutide by Boehringer Ingelheim, Oregovomab by Eli Lilly, Retevmo by Eli Lilly, Cagrisema by Novo Nordisk, RGT-075 by Regor Therapeutics, and others, is expected to create a positive impact on the obesity market further.

Obesity Recent Developments

• In August 2025, Teva Pharmaceuticals announced FDA approval and U.S. launch of a generic version of Saxenda® (liraglutide injection).
• In August 2025, Eli Lilly announced positive Phase 3 results for orforglipron, its oral GLP-1 receptor agonist, showing significant weight loss and A1C reduction in adults with obesity or overweight and type 2 diabetes.
• In August 2025, Signos launched the Signos Glucose Monitoring System, the first FDA-cleared, over-the-counter glucose monitoring system designed for weight management. The system integrates the Stelo by Dexcom glucose biosensor with an AI-powered platform, providing personalized, real-time insights into how food, activity, stress, and sleep impact metabolic health.
• In July 2025, FuturHealth began offering members easy access to FDA-approved GLP-1 weight-loss medications, including Wegovy®, with affordable cash-pay prices and free next-day home delivery via Alto Pharmacy. A special $299 first-month offer for Wegovy® is available through July 31, with ongoing pricing at $499 per month.
• In July 2025, Caliway Biopharmaceuticals announced that the U.S. FDA cleared the pivotal Phase 3 study SUPREME-01 for CBL-514, an investigational drug for large-area localized fat reduction.
• In June 2025, Laekna (2105.HK) submitted an Investigational New Drug (IND) application to the U.S. FDA for LAE103, a monoclonal antibody targeting ActRIIB to treat sarcopenic obesity and muscle-related diseases. This complements LAE102, an ActRIIA-selective antibody, as part of Laekna’s innovative ActRII portfolio aimed at metabolic patients needing new therapies.
• In June 2025, the FDA cleared Levita Magnetics’ Magnetic Surgical System combined with MARS® for bariatric and hiatal hernia repair, enabling less invasive treatment of obesity-related conditions.
• In May 2025, Eli Lilly’s Zepbound demonstrated a “superior benefit-risk ratio” compared to Novo Nordisk’s Wegovy, showing greater weight loss without compromising safety. New trial data confirmed Zepbound’s advantage in the competitive GLP-1 obesity treatment market, according to Leerink analysts.
• In April 2025, Novo Nordisk announced an expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg by partnering with select telehealth providers. This collaboration with NovoCare® Pharmacy allows self-paying patients to access authentic, FDA-approved Wegovy® through a simplified pathway, with CenterWell Pharmacy managing prescription fulfillment and delivery. Telehealth providers such as Hims & Hers Health, Inc., LifeMD, and Ro will now have direct access to the treatment.
• In April 2025, Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND meeting, supporting the advancement of its EL-22 program in combination with GLP-1 receptor agonists toward a Phase 2 clinical trial.
• In March 2025, Palatin Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition.
• In March 2025, Ascletis Pharma Inc.  reported promising pharmacokinetic and weight loss results from its ASC47 Phase Ib single subcutaneous injection studies in Australia, involving healthy subjects with elevated LDL-C and patients with obesity.
• In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk's efforts to meet the needs of individuals living with obesity, following the FDA's confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand.
• In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance.
• In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company's early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action.
• In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly’s rival GLP-1 drug Zepbound may still have an advantage over Wegovy.
• In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.
• In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly’s reply due by January 21.
• On September 10, 2024, Immunis, Inc., a biotech firm focused on secretome therapeutics for age-related and immune disorders, received FDA approval to advance its Phase II clinical trial of IMMUNA, aimed at reversing sarcopenic obesity. This follows the completion of secretome treatments for its third patient cohort in a Phase I/IIa trial addressing age-related muscle atrophy.
• On September 9, 2024, Terns Pharmaceuticals announced positive top-line results from its Phase 1 trial evaluating TERN-601 in healthy adults with obesity or overweight. The randomized, double-blind, placebo-controlled trial assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of once-daily dosing of TERN-601, showing promising results for this small-molecule treatment.
• In June 2024, researchers at Children's Hospital of Philadelphia (CHOP) revealed mechanisms behind a molecule's role in regulating insulin sensitivity, potentially paving the way for a new therapeutic target for obesity-related type 2 diabetes.
• In June 2024, Novo Nordisk and Eli Lilly dominated the obesity market, with Novo Nordisk generating $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss drugs in Q1 2024.
• In June 2024, the US House Ways and Means Committee proposed a strategy for Medicare to cover GLP-1 weight-loss drugs like Wegovy and Zepbound.
• In June 2024, Zealand Pharma announced a share issuance to raise DKK 7 billion ($1 billion) to advance its obesity candidates.
• In June 2024, Form Health raised $38 million in a Series B round to accelerate its science-based obesity care initiatives and enhance its telehealth platform.
• In June 2024, Novo Nordisk announced a $4.1 billion investment to build a new factory in North Carolina to expand production of Wegovy and Ozempic.
• In June 2024, researchers found that the decline in coronary heart disease rates among people under 60 in the UK stalled, likely due to rising obesity rates.
• In June 2024, three studies presented at the ADA's 84th Scientific Sessions showcased new data on drug therapy innovations for obesity, including insights on GLP-1 receptor agonists.
• In June 2024, Altimmune, Inc. presented data from its Phase II MOMENTUM trial of pemvidutide, a GLP-1/glucagon dual receptor agonist candidate, at the ADA's 84th Scientific Sessions.
• In June 2024, Eli Lilly received NICE endorsement for tirzepatide in treating obesity, with some caveats for usage alongside diet and exercise changes.
• In May 2024, a study in the Journal of Clinical Endocrinology & Metabolism assessed body fat percentage thresholds to define overweight and obesity, correlating with metabolic syndrome.
• In May 2024, Terns Pharmaceuticals announced senior management participation in a virtual chat at UBS Obesity Therapeutics Day.
• In May 2024, research at the European Congress on Obesity quantified the long-term health impact of childhood obesity on life expectancy.
• In April 2024, Metsera launched with a portfolio of weight loss drugs, aiming to compete with Novo Nordisk and Eli Lilly.
• In April 2024, Metsera emerged from stealth with $290 million to develop new obesity and metabolic disease medicines.
• In March 2024, Viking Therapeutics saw a 16.8% stock increase after positive early-stage data for its obesity drug VK2735.
• In March 2024, the Centers for Medicare and Medicaid Services was expected to negotiate pricing for Novo Nordisk’s obesity therapy Wegovy.
• In March 2024, Eli Lilly launched the next phase of its Get Better branding campaign, focusing on obesity.
• In February 2024, Boehringer Ingelheim revealed Phase II data for survodutide, showing significant improvements in metabolic dysfunction-associated steatohepatitis patients.
• In January 2024, Adipo Therapeutics completed a $1.9 million bridge fund round to develop treatments for obesity and type 2 diabetes.

Obesity Treatment Market

Obesity Overview, Country-Specific Treatment Guidelines and Diagnosis

Obesity is a chronic medical condition characterized by excessive body fat accumulation, which increases the risk of various health issues such as diabetes, cardiovascular diseases, and metabolic disorders. It is primarily measured using the Body Mass Index (BMI), where a BMI of 30 or higher is classified as obese. Obesity results from a combination of genetic, behavioral, environmental, and hormonal factors.

Types of Obesity:

1. Hypothalamic Obesity – Caused by damage to the hypothalamus, leading to impaired hunger regulation and excessive weight gain.

2. Pediatric Obesity – Obesity occurring in children and adolescents, often due to poor diet, lack of physical activity, and genetic factors.

3. HET Obesity/POMC Deficiency Obesity – A rare genetic disorder where mutations in the POMC gene disrupt appetite control, leading to severe early-onset obesity.

4. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity – These conditions result from mutations affecting appetite regulation, causing excessive hunger and severe obesity from an early age.

5. Syndromic and Monogenic Obesity – Rare forms of obesity caused by single-gene mutations or genetic syndromes (e.g., Prader-Willi Syndrome), often accompanied by developmental and metabolic disorders.

Early diagnosis and intervention is the most successful strategy for obesity treatment. Diagnosis of obesity involves proper evaluation of the weight status, which considers many factors and uses various tools and diagnostic tests, including body mass index (BMI), waist circumference measurement, physical exams, and lab tests to check for comorbidities.

The obesity report provides an overview of obesity pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Also, Read @ XENICAL Drug Insight

Further details related to country-based variations in diagnosis are provided in the report...

Obesity Treatment

The management of obesity and its associated comorbidities has blown over time. The current treatment of obesity aims to reduce body weight and body fat percentage to prevent the onset of obesity-related health problems and improve the overall health condition of the patient. In the last century, the pharmacological management of obesity has included amphetamines, thyroid hormones, dinitrophenol and various drug combinations (rainbow pills) that were withdrawn shortly after regulatory approval due to serious adverse effect.

Approved treatments for obesity – particularly pharmacotherapy – mostly remain underutilized. The reasons underlying the low uptake of medical therapy for obesity are complex, ranging from practical issues of insurance coverage and cost to concerns about safety and efficacy, as well as continued disease-related stigma, even among providers. The weight-loss medications that are approved by the US FDA include, CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), XENICAL (orlistat), QSYMIA (phentermine-topiramate), WEGOVY (semaglutide), IMCIVREE (setmelanotide), and others.

Know More @ QSYMIA Drug Insight

Further details related to country-based variations in treatment are provided in the report...

Obesity Epidemiology

The obesity epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The obesity epidemiology is segmented with detailed insights into Total Prevalent Cases of Obesity, Total Obesity Patients Seeking Help, and Total Treated Cases of Obesity.

• As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7 MM in 2023.
• DelveInsight’s consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023.
• According to the findings, treatment rate for children was found to be less than that of adults across countries.
• Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany.

Obesity Drug Chapters

The drug chapter segment of the obesity report encloses a detailed analysis of obesity marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the obesity pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Obesity Drugs

IMCIVREE (setmelanotide): Rhythm Pharmaceuticals

Imcivree is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity. In November 2020, Rhythm Pharmaceuticals announced the US FDA approval of Imcivree as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency. Earlier, in May 2017, FDA expanded the Breakthrough Therapy Designation to disorders involving genetic defects upstream of the melanocortin-4 receptor in the leptin-melanocortin pathway.

ZEPBOUND (tirzepatide): Eli Lilly and Company

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In November 2023, the US FDA approved Eli Lilly and Company's ZEPBOUND (tirzepatide) injection, the first obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors. ZEPBOUND is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, Type II diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.

You may read this @ CONTRAVE Drug Insight

Note: Detailed marketed therapies assessment will be provided in the final report...

Emerging Obesity Drugs

Semaglutide oral: Novo Nordisk

Oral semaglutide is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan under the trade name, RYBELSUS. It is an oral GLP-1 RA, an analogue of the naturally occurring hormone GLP-1. Currently, the company is developing the candidate for obesity. The candidate is being evaluated in various Phase III trials (OASIS 1, OASIS 2, OASIS 3 and OASIS 4) to assess the safety and efficacy of the drug in subjects with overweight or obesity.

In May 2023, Novo Nordisk reported positive result from one of the Phase III trials, i.e. OASIS 1, which met primary endpoint.

Survodutide (BI 456906): Boehringer Ingelhium

Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium. GLP1 agonism is expected to lower body weight and provide glucose control. Both receptors are critical to controlling metabolic functions. The compound leverages the known effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans as well as the established effects of GLP1 agonism on both glucose control and body weight. The dual agonist BI 456906 has potential as a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. In Augustt 2023, Boehringer Ingelheim announced its plans to advance survodutide into three registrational Phase III studies for people living with overweight or obesity. Currently, it is being evaluated under Phase III development.

Read More @ SAXENDA Drug Insight

Note: Detailed emerging therapies assessment will be provided in the final report...

Obesity Market Outlook

Key players, such as Novo Nordisk, Boehringer Ingelhium, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of obesity.

• The United States represents approximately 80% of the Obesity market size, surpassing the combined market size of Germany, Spain, Italy, France (referred to as EU4), the United Kingdom, and Japan.
• By 2034, WEGOVY (Simaglutide) and ZEPBOUND (tirzepatide) are anticipated to achieve the prominent Obesity market share in the 7 major markets.
• Germany accounts for the second highest Obesity market size in the 7MM during the forecast period 2024–2034.
• The Obesity market size is expected to grow significantly during the forecast period owing to launch of novel therapies and increasing prevalence of obesity.

Obesity Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Know More @ WEGOVY Drug Insight

Further detailed analysis of emerging therapies drug uptake in the report...

Obesity Pipeline Activities

The Obesity market report provides insights into different Obesity clinical trials within Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Obesity market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for obesity emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 20+ KOLs in the 7MM. Centers such as Harvard Medical School, World Obesity Federation, Showa University, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of obesity. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Get More Details @ IMCIVREE Drug Insight

Obesity Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers’ concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently.

The Obesity market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Obesity Market Report

• The Obesity market report covers a segment of key events, an executive summary, descriptive overview of obesity, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging Obesity therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the obesity market, historical and forecasted Obesity market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Obesity market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM obesity market.

Obesity Market Report Insights

• Obesity Patient Population
• Obesity Therapeutic Approaches
• Obesity Pipeline Analysis
• Obesity Market Size
• Obesity Market Trends
• Existing and Future Obesity Market Opportunity

Obesity Market Report Key Strengths

• Eleven-year Forecast
• 7MM Coverage
• Obesity Epidemiology Segmentation
• Inclusion of Country Specific Treatment Guidelines
• KOL’s Feedback On Approved and Emerging Obesity Therapies
• Key Cross Competition
• Conjoint Analysis
• Obesity Drugs Uptake
• Key Obesity Market Forecast Assumptions

Obesity Market Report Assessment

• Current Obesity Treatment Practices
• Obesity Unmet Needs
• Obesity Pipeline Product Profiles
• Obesity Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the growth rate of the 7MM obesity treatment market?
• What was the total Obesity market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label Obesity therapies?
• How would the Obesity market drivers, barriers, and future opportunities affect the Obesity market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of obesity?
• How many companies are developing therapies for the treatment of obesity?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing Obesity therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Obesity therapies?

Reasons to buy

• The Obesity market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the obesity market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Obesity market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Obesity market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging Obesity therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Obesity market so that the upcoming players can strengthen their development and launch strategy.

Unlock a Wealth of Insights with Related Articles, Video, and Infographics:- 

• Obesity: A Worldwide Pandemic with Advancing Management Options
• Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?
• The Obesity Pandemic: What can we do about it?
• Obesity Treatment Market: Infographics
• Obesity Market: Video

Stay Updated with Us @ Latest DelveInsight Blog